Quarterly Earnings

Shedding its IT baggage, Vaso Corp's Q2 results reveal a focused, profitable healthcare strategy. Is this the new blueprint for MedTech success?

Reading International posts record post-pandemic profits, fueled by a stellar film slate. But beneath the surface, a surge in short-term debt reveals a high-stakes balancing act.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

As Evaxion prepares its Q2 update, investors watch to see if its AI-Immunology™ platform can deliver the financial and clinical results for long-term value.

Saudi Aramco's record profits defy a global crisis. The real story isn't just blockades, but an invisible chokepoint in the insurance market.

Zoomcar's latest earnings are a masterclass in strategic pivots. By prioritizing high-value trips over volume, the Indian car-sharing giant is finding profit.

With a new CEO, a leaner budget, and crucial data on the horizon for its brain and obesity drugs, Neumora is navigating a pivotal phase of growth.

RCM Technologies' stellar 20% revenue growth is fueled by a massive engineering surge, but a closer look at margins reveals a high-stakes strategic maneuver.

With fully funded facilities and a US Army pact, REalloys is building a non-Chinese magnet supply chain. But can its strategic wins outweigh a $37M loss?

Binah Capital Group swings from a loss to a profit in Q2, crediting its unique model for empowering independent advisors. Is this a fluke or a new industry benchmark?

Firm Capital reports falling profits but holds its dividend steady. With a high payout ratio and a surge in new lending, is this a sign of resilience or risk?

Stardust Power is breaking ground on a key US lithium refinery, but thin cash reserves and a reliance on future funding raise critical questions.

Greenlane Renewables posts a profit while doubling R&D and forging a key partnership with Panasonic. Is this the model for sustainable innovation?

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

Intellicheck posts record Q2 revenue and a fifth straight profitable quarter, but a key client's pivot to a multi-vendor model tests its diversification strategy.

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

MDB Capital celebrates a string of successful IPOs but reports a staggering $16.1M loss, putting its unique 'public venture' model under intense scrutiny.

With regulatory winds at its back in the US and EU, Cibus is pushing to commercialize its non-GMO tech. Can new leadership turn R&D into revenue before cash runs out?

dLocal posts a stunning 92% surge in payment volume, cementing its emerging market dominance. Yet, a closer look at profitability reveals a complex balancing act.